BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16614247)

  • 1. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.
    Liso A; Capello D; Marafioti T; Tiacci E; Cerri M; Distler V; Paulli M; Carbone A; Delsol G; Campo E; Pileri S; Pasqualucci L; Gaidano G; Falini B
    Blood; 2006 Aug; 108(3):1013-20. PubMed ID: 16614247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma.
    Gaidano G; Pasqualucci L; Capello D; Berra E; Deambrogi C; Rossi D; Maria Larocca L; Gloghini A; Carbone A; Dalla-Favera R
    Blood; 2003 Sep; 102(5):1833-41. PubMed ID: 12714522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
    Hartmann S; Schuhmacher B; Rausch T; Fuller L; Döring C; Weniger M; Lollies A; Weiser C; Thurner L; Rengstl B; Brunnberg U; Vornanen M; Pfreundschuh M; Benes V; Küppers R; Newrzela S; Hansmann ML
    Leukemia; 2016 Apr; 30(4):844-53. PubMed ID: 26658840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation.
    Montesinos-Rongen M; Van Roost D; Schaller C; Wiestler OD; Deckert M
    Blood; 2004 Mar; 103(5):1869-75. PubMed ID: 14592832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Moore EM; Swerdlow SH; Gibson SE
    Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
    Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
    Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
    Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
    Agaimy A; Wild V; Märkl B; Wachter DL; Hartmann A; Rosenwald A; Ihrler S
    Am J Surg Pathol; 2015 Sep; 39(9):1206-12. PubMed ID: 25929348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.
    Schumacher MA; Schmitz R; Brune V; Tiacci E; Döring C; Hansmann ML; Siebert R; Küppers R
    Haematologica; 2010 Jan; 95(1):153-7. PubMed ID: 19648161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation.
    Deutsch AJ; Frühwirth M; Aigelsreiter A; Cerroni L; Neumeister P
    J Invest Dermatol; 2009 Feb; 129(2):476-9. PubMed ID: 18704108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology.
    Hartmann S; Eray M; Döring C; Lehtinen T; Brunnberg U; Kujala P; Vornanen M; Hansmann ML
    BMC Cancer; 2014 May; 14():332. PubMed ID: 24885870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
    Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
    Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
    Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Schuhmacher B; Bein J; Rausch T; Benes V; Tousseyn T; Vornanen M; Ponzoni M; Thurner L; Gascoyne R; Steidl C; Küppers R; Hansmann ML; Hartmann S
    Haematologica; 2019 Feb; 104(2):330-337. PubMed ID: 30213827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection.
    Libra M; Capello D; Gloghini A; Laura P; Berra E; Cerri M; Gasparotto D; Franca S; De Re V; Gaidano G; Carbone A
    J Pathol; 2005 May; 206(1):87-91. PubMed ID: 15809970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation.
    Deutsch AJ; Aigelsreiter A; Staber PB; Beham A; Linkesch W; Guelly C; Brezinschek RI; Fruhwirth M; Emberger W; Buettner M; Beham-Schmid C; Neumeister P
    Blood; 2007 Apr; 109(8):3500-4. PubMed ID: 17197434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
    Tian X; Xu J; Dorfman DM
    Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
    Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
    Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.